Seasonal respiratory viral infection: how will you support your patients this winter?

Respiratory viral infections occur more frequently during the winter monthsand are a risk factor for respiratory exacerbations:2,3

Upper respiratory infections represent a significant disease burden with 17.2 billion incident cases in 2019 globally.4

Respiratory exacerbations, when associated with viral respiratory infections, are typically more severe, last longer and increase the risk of hospitalisation.2,3

There are several factors to consider when choosing an aerosol drug delivery device:

Fugitive emissions

Fugitive emissions are a concern when patients are harbouring respiratory viral infections.2


Support during escalation of care

Patients admitted to hospital during exacerbations may receive respiratory support (e.g., high-flow therapy [HF]) or ventilatory support (e.g., non-invasive ventilation [NIV], invasive mechanical ventilation [IMV]).2,3

Patient distress during respiratory exacerbations

On presentation, children may be crying or in distress, which may negatively impact the dose delivered during inhaled therapy. 5,6

Aerogen: supporting you through winter

In a study of patients in an emergency department requiring treatment with an aerosolised bronchodilator:

of patients achieved symptom control with one 2.5 mg salbutamol dose 7

median reduction in ED length of stay per patient with Aerogen Ultra versus jet nebuliser 7

reduction in admission rates with Aerogen Ultra versus jet nebuliser 7

higher discharge rate with Aerogen Ultra versus jet nebuliser 7

Aerogen helps mitigate fugitive emissions8,9

Significantly lower fugitive aerosol concentrations were reported with Aerogen and mask or mouthpiece versus jet nebuliser during self-ventilation (P<0.05)†8

Aerogen can be used throughout the hospital10

If escalation of care is required, the Aerogen Solo system can facilitate aerosol drug delivery at every stage of a patient's respiratory journey (SV, HF, NIV, IMV),10 supporting continuity of care.

Aerogen supports a calm environment

Quick and easy to set up10

Virtually silent during drug delivery10,11

Compatible with all standard aerosol/valved face masks, to meet varied patient needs10

Aerogen Solo

Aerogen Solo can support aerosol drug delivery at every stage of a patient’s respiratory journey: during IMV, NIV, HF and SV.1


  • Quick and easy to set up10
  • Virtually silent10,11
  • Single patient use10
  • 28 days intermittent or 7 days continuous use10
  • No added flow10
  • Refill medication cup without opening the circuit10
  • 6 mL cup10
  • Can be placed at the wye or at the humidifier10


Aerogen Solo, virtually silent
Invasive mechanical ventilation enquiries

Enquiries

The Aerogen team and our representatives are available globally to answer your questions, provide an online demonstration and place orders

How can we help

Defined as fugitive aerosol concentrations with jet nebuliser vs Aerogen with a mask at particle sizes of 1.0–5 μm and with a mouthpiece at particle sizes of 0.5–3 μm (all P<0.05) when self-ventilating. Study performed in healthy subjects.